MENU

IPHA Stock Innate Pharma SA (IPHA, $2.17) price exceeded its 50-day Moving Average on October 04, 2024

A.I.dvisor
at Tickeron.com
10/05/24
Loading...
IPHA - Innate Pharma SA
Moving Avg. signal
Bearish Trend
Odds of DOWN Trend
Moving Avg. signal
Price: $2.1683
Daily change: -$0.1017 (-4.48%)
Daily volume: 1.9K
Industry: Biotechnology
This price move could indicate a change in the trend, and may be a sell signal for investors. A.I.dvisor found 73 similar cases, and were successful. Based on this data, the odds of success are

Momentum Indicator for IPHA turns negative, indicating new downward trend

IPHA saw its Momentum Indicator move below the 0 level on October 04, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 120 similar instances where the indicator turned negative. In of the 120 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IPHA turned negative on September 13, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

IPHA moved below its 50-day moving average on October 04, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IPHA crossed bearishly below the 50-day moving average on September 25, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for IPHA entered a downward trend on October 16, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where IPHA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .

IPHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.701) is normal, around the industry mean (12.582). P/E Ratio (0.000) is within average values for comparable stocks, (110.042). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.002). IPHA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (6.588) is also within normal values, averaging (223.593).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IPHA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
IPHA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
117, Avenue de Luminy
Phone
+33 430303030
Employees
211
Web
https://www.innate-pharma.com